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exacerbate progression of the disease (1, 2). Renal deposi-
tion of apoB and apoE accelerates the progression of 
glomerulosclerosis in many renal diseases (3). While it is 
unknown how lipid accumulates in the mesangium, we previ-
ously demonstrated that renal proteoglycans have a binding 
affinity for LDL in the physiological range (4). Proteogly-
cans are a class of matrix molecules composed of glycos-
aminoglycan (GAG) side chains attached to core proteins; 
proteoglycans are classified based on their core protein 
and GAG structure. Proteoglycans can bind lipoproteins 
via ionic interactions between negatively charged sulfate 
and carboxyl groups on their GAG chains and positively 
charged residues on apoB and apoE. Proteoglycan binding 
of LDL induces irreversible changes in the conformation 
of apoB inhibiting particle efflux and increasing suscepti-
bility to modifications, such as oxidation. Oxidized lipopro-
teins are avidly taken up by macrophages leading to foam 
cell formation [for review see (5)].
Transforming growth factor- (TGF-) is known to be 
elevated in diabetes and critically involved in the initiation 
and progression of DN [for review see (6)]. The literature 
suggests that hyperlipidemia may contribute to elevated 
TGF- levels (7), possibly due to increased angiotensin II 
or due to effects of hyperlipidemia worsening glomerular 
pathology, which would lead to increased TGF- synthesis. 
TGF- has been shown to mediate the accumulation of 
proteoglycans, such as biglycan, in the extracellular matrix 
(ECM) (8, 9). Furthermore, we have previously shown that 
TGF- increases the size and LDL binding affinity of pro-
teoglycans (10, 11). Biglycan is a small leucine-rich proteo-
glycan with two GAG side chains attached to its core 
protein. Increased circulatory biglycan is seen in a number 
of pro-inflammatory renal diseases, including transplant 
rejection and lupus nephritis (12). Renal biglycan has been 
Abstract Animal studies demonstrate that hyperlipidemia 
and renal lipid accumulation contribute to the pathogenesis 
of diabetic nephropathy (DN). We previously demonstrated 
that renal lipoproteins colocalize with biglycan, a renal pro-
teoglycan. The purpose of this study was to determine whether 
prevention of renal lipid (apoB) accumulation attenuates DN. 
Biglycan-deficient and biglycan wild-type Ldlr/ mice were 
made diabetic via streptozotocin and fed a high cholesterol 
diet. As biglycan deficiency is associated with elevated trans-
forming growth factor- (TGF-), in some experiments mice 
were injected with either the TGF--neutralizing antibody, 
1D11, or with 13C4, an irrelevant control antibody. Biglycan 
deficiency had no significant effect on renal apoB accumula-
tion, but led to modest attenuation of DN with 30% reduc-
tion in albuminuria; however, biglycan deficiency caused a 
striking elevation in TGF-. Use of 1D11 led to sustained 
suppression of TGF- for approximately 8 weeks at a time. 
The 1D11 treatment caused decreased renal apoB accumula-
tion, decreased albuminuria, decreased renal hypertrophy, 
and improved survival, compared with the 13C4 treatment.  
Thus, prevention of renal apoB accumulation is protective 
against development of DN. Furthermore, this study demon-
strates that prevention of renal apoB accumulation is a mecha-
nism by which TGF- inhibition is nephroprotective.— 
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Diabetic nephropathy (DN) is the leading cause of end 
stage renal disease in the Western world. Dyslipidemia is 
highly prevalent in patients with nephropathy and can 
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shown to be elevated in diabetes and in fibrotic disease 
(13–16). Biglycan is well-known to be upregulated by TGF-. 
However, the relationship between TGF- and biglycan is 
complicated, as biglycan (and another related proteogly-
can called decorin) have been proposed to be natural in-
hibitors of TGF-, as they can bind TGF- and sequester it 
in the ECM [for review see (17)]. It has been shown that 
the absence of biglycan in the ECM prevents TGF- seques-
tration within the ECM, leading to overactive TGF- signal-
ing (18). Several studies have also reported increased 
TGF- levels in biglycan- or decorin-deficient mice, provid-
ing further evidence that proteoglycans may act as natural 
inhibitors of TGF- (19–22).
Previously, we reported that diabetes and hyperlipidemia 
led to continuous renal injury characterized by increased 
urine albumin excretion, elevated TGF-, renal and glomer-
ular hypertrophy, mesangial matrix expansion, and glomer-
ular lipid and apoB accumulation (15, 16). Furthermore, 
lowering dietary cholesterol in these mice improved renal 
function by reversing renal injury (15). By immunohisto-
chemistry, we demonstrated colocalization of renal apoB 
with biglycan (16). Thus, we proposed that renal apoB re-
tention may be mediated by accumulation of renal bigly-
can (16). The goal of this study was to determine whether 
biglycan deficiency protected against DN. As biglycan defi-
ciency causes increased TGF-, which can confound find-
ings, these studies were done in the presence or absence of 
TGF- inhibition.
MATERIALS AND METHODS
Animals
Male biglycan-deficient and biglycan wild-type mice were crossed 
with LDL receptor-deficient (Ldlr/) mice (C57BL6 background) 
as previously described (19, 23). The studies were approved by the 
Institutional Animal Care and Use Committee in adherence with 
the National Institutes of Health Guide for the Care and Use of Labo-
ratory Animals. Diabetes was induced via streptozotocin (STZ) in-
jections as described; nondiabetic control groups received citrate 
vehicle injections (15, 16). In some experiments, mice were con-
currently injected intraperitoneally with 2 mg/kg body weight 
TGF--neutralizing antibody, 1D11 (R&D Systems, Minneapolis, 
MN), or irrelevant control antibody, 13C4 (Genscript, Piscataway, 
NJ), on the first day of STZ injections. Injections with 1D11 or 
13C4 were repeated every 8 weeks. All mice were fed a 0.12% g/kg 
cholesterol diet with 40% calories from fat (TD000242; Harlan 
Teklad, Madison, WI) (15, 16) for 26 weeks; time 0 is defined as 
the first day of diet and is 2 weeks after STZ or vehicle was first 
administered.
Metabolic and renal characterization
Animal studies were performed as previously described (15, 
16). Briefly, glucose was measured at least weekly by tail vein prick 
using a commercial glucose meter. Mice received insulin via 
placement of subcutaneous pellets as needed (indicated by weight 
loss, body condition, or blood glucose over 500 mg/dl). Nonfast-
ing blood samples were collected periodically to measure TGF- 
and cholesterol, as previously described (15, 16). Mice were placed 
individually into metabolic cages every 4 weeks for collection of 24 h 
urine samples for measurement of albumin (Bethyl Laboratories, 
Montgomery, TX) and creatinine (R&D Systems). Blood pressure 
was measured by the tail cuff method in week 25 following a week 
of acclimation to the apparatus, as previously described (15, 16). 
After 26 weeks of diet and diabetes, mice were euthanized by le-
thal anesthesia and tissues were collected. Kidneys were decapsu-
lated, weighed, and divided. Portions of kidneys were snap-frozen 
in liquid nitrogen, fixed in 10% formalin, and then embedded in 
paraffin, fixed in methyl Carnoy, or frozen in OCT. Renal sections 
(4 m thick) were stained with periodic acid Schiff (PAS), Mas-
son’s trichrome, or oil red O, or immunostained for apoB (cata-
log number K23300R; Meridian Life Sciences, Memphis, TN), as 
previously described (16), and matrix accumulation was scored 
and glomerular cross-sectional area was measured by two blinded 
observers and scores averaged. Total renal protein was immunob-
lotted for apoB and proteoglycans as previously described (15, 16, 
23) (the relative amount of apoB48 was very low, so only apoB100
is shown in the blots).
Renal TGF-
Frozen kidney tissues were weighed and pulverized, then homog-
enized in a hypotonic buffer with protease inhibitors (24). The 
homogenate was centrifuged at 15,000 g at 4°C for 20 min and the 
supernatant was removed, aliquoted, and frozen at 80°C. Pro-
tein concentrations were determined by standard Bradford assay 
(Bio-Rad, Hercules, CA). The supernatant was used to measure 
renal TGF- by ELISA (Promega, Madison, WI), which was nor-
malized to total renal protein. Acid activation of homogenate was 
used to measure total TGF-, while an aliquot of nonactivated ho-
mogenate was used to measure biologically active TGF- accord-
ing to the assay protocol.
LDL binding assay
Primary mesangial cells were isolated from 4- to 5-week-old non-
diabetic biglycan-deficient and biglycan wild-type mice and used 
in an LDL binding assay in vitro, as previously described (25). In 
some experiments, cells were stimulated with TGF- (2 ng/ml) 
and 1D11 or 13C4 (10 g/ml) for 24 h, then washed prior to in-
cubation with LDL. Cell protein was collected from parallel wells 
for analysis of biglycan by immunoblot.
Statistics
Data are presented as mean ± SEM unless otherwise specified 
or clear from the context. Most data analyses were based on a 2 × 
2 factorial structure with diabetic status and genotype (see Table 1; 
Figs. 1, 2) or genotype and treatment (see Table 2; Figs. 3, 4) as the 
two factors. Males were not directly compared with females. If sig-
nificant interactions between diabetic status and genotype (or 
genotype and treatment) were detected, pairwise comparisons 
within each genotype and diabetic status (or genotype and treat-
ment) stratum were performed, adjusted for multiplicity using 
the Bonferroni method; otherwise, inferences were based on the 
presence or absence of significant main effects. For most quantita-
tive outcomes collected longitudinally, test results for interactions 
and main effects are reported based on overall trajectories, trajec-
tory slopes, or areas under trajectory curves, as estimated from 
linear mixed modeling. For quantitative outcomes analyzed at 
one time point, test results for interactions and main effects are 
based on two-way ANOVA, which may have included log transfor-
mations to reduce nonnormality and/or weights to address differ-
ent within-group variances. Survival was compared by log rank or 
Fisher’s exact test. Insulin pellet consumption was assessed for 
diabetic mice only using negative binomial or zero-inflated Pois-
son regression for number of pellets received. Data analyses were 
performed using version 9.3 of SAS or SigmaPlot 12.0. Statistical 
significance was defined by P < 0.05.
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RESULTS
Metabolic characterization of biglycan deficiency
As previously reported, biglycan-deficient mice were 
smaller than biglycan wild-type mice (19). For male mice, 
weight gain was significantly decreased in diabetic com-
pared with nondiabetic mice (P < 0.001) and in biglycan-
deficient compared with biglycan wild-type mice (P = 
0.001). For female mice, there was a significant interaction 
between diabetes status and genotype (P < 0.001; Table 1). 
Biglycan deficiency had no impact on susceptibility to STZ-
induced diabetes and all mice that received STZ had ele-
vated glucose levels compared with control mice (P < 0.001 
for diabetic vs. nondiabetic mice for both genders; Fig. 1A, 
B). Mice received insulin via placement of subcutaneous 
pellets as needed; nondiabetic mice did not require insu-
lin. Biglycan-deficient male mice needed more insulin than 
biglycan wild-type mice (P = 0.035); however, there were no 
significant differences in insulin use between female biglycan-
deficient or biglycan wild-type diabetic mice (Table 1). 
Per study protocol, mice that did not respond to insulin or 
had poor body condition were euthanized. There were no 
significant differences between groups in male mice, but 
female diabetic mice of both genotypes had decreased sur-
vival compared with female nondiabetic mice (P = 0.012); 
there was no significant effect of biglycan genotype on sur-
vival (Table 1). As previously described (15), plasma cho-
lesterol increased over time while mice were fed the 0.12% 
cholesterol diet. There were no significant differences in 
cholesterol levels between groups in male mice. Female 
biglycan-deficient mice had significantly higher cholesterol 
levels than female biglycan wild-type mice at study end (P < 
0.001), but there was no significant effect of diabetes (Ta-
ble 1). In male mice, triglycerides did not differ signifi-
cantly between groups; however, in female mice, there 
was a significant interaction between diabetes and genotype 
(P = 0.033; Table 1). Systolic blood pressure was increased 
in male diabetic biglycan wild-type mice compared with 
male nondiabetic biglycan wild-type mice (P = 0.026; Table 1; 
there was a significant interaction between biglycan geno-
type and diabetes status, P = 0.004). There were no signifi-
cant differences between group blood pressures in female 
mice (Table 1).
Elevated TGF- in biglycan deficiency
As previously described (19), biglycan-deficient mice 
(both males and females) had higher plasma TGF- levels 
both at baseline and throughout the study; diabetes caused 
an increase in plasma TGF- levels over time. Thus, dia-
betic biglycan-deficient mice had the highest plasma TGF- 
levels over the study. For both male and female mice, there 
was a significant interaction between diabetes status and 
genotype (P < 0.001 for both males and females). For male 
mice, there were statistically significant differences between 
groups by pairwise comparisons (P = 0.026 for biglycan 
genotype in nondiabetic mice and P < 0.001 for other com-
parisons; Fig. 1C). For female mice, there were statisti-
cally significant differences between groups (P < 0.001 for 
each comparison; Fig. 1D). Renal TGF- was measured af-
ter 26 weeks. Total renal TGF- was increased by diabetes 
TABLE 1. Effect of biglycan deficiency on metabolic parameters
Bgn+/+ Control Bgn+/+ DM Bgn/ Control Bgn/ DM P
Weight gain, male (g) 5.9 ± 0.6 5.0 ± 0.4 5.2 ± 0.4 4.8 ± 0.4 <0.001 for diabetes and 0.001 for genotype
Weight gain, female (g) 6.2 ± 0.4 3.6 ± 0.6a 6.4 ± 0.6b 4.0 ± 0.5a,b <0.001 for interaction between diabetes 
and genotype
Insulin use, males (n treated/total n) 0/13 (0%) 4/26 (15%) 0/16 (0%) 14/35 (40%) 0.035 for genotype
Insulin use, females (n treated/total n) 0/10 (0%) 20/28 (71%) 0/12 (0%) 16/24 (67%) NS for genotype
Survival, male N (%) 12/13 (92%) 25/26 (96%) 16/16 (100%) 31/35 (89%) NS
Survival, female N (%) 10/10 (100%) 19/28 (68%) 12/12 (100%) 20/24 (83%) 0.012 for diabetes
Cholesterol, male 1,369 ± 210 1,373 ± 137 1,570 ± 163 1,598 ± 113 NS
Cholesterol, female 963 ± 79 1,073 ± 66 1,426 ± 167 1,595 ± 145 <0.001 for genotype
Triglycerides, male 160 ± 21 150 ± 43 213 ± 53 168 ± 30 NS
Triglycerides, female 102 ± 20 178 ± 74 79 ± 19 495 ± 76a,b 0.033 for interaction between diabetes and 
genotype
sBP, male (mm Hg) 109 ± 2 118 ± 2a 116 ± 3 111 ± 6 0.004 for interaction between diabetes and 
genotype
sBP, female (mm Hg) 111 ± 2 108 ± 3 109 ± 5 104 ± 2 NS
Total renal TGF-, males (pg/mg) 119 ± 2.5 230 ± 10.9a 160 ± 6.7b 690 ± 135.7a,b 0.006 for interaction
Total renal TGF-, females (pg/mg) 113 ± 5.2 227 ± 37.9 176 ± 21.6 677 ± 239.3 0.02 for diabetes; 0.048 for genotype
Bioactive renal TGF-, males (pg/mg) 10 ± 1.0 17 ± 0.8 12 ± 1.0 21 ± 1.9 <0.001 for diabetes; 0.016 for genotype,
Bioactive renal TGF-, females (pg/mg) 7 ± 0.3 13 ± 0.8 12 ± 2.4 18 ± 5.5 NS (0.053 for diabetes)
Renal weight/body weight, males  
(mg/g)
3.7 ± 0.2 5.9 ± 0.4a 3.9 ± 0.2 4.8 ± 0.2a 0.016 for interaction between diabetes and 
genotype
Renal weight/body weight, females 
(mg/g)
3.7 ± 0.2 6.3 ± 0.5 4.2 ± 0.3 6.2 ± 0.4 0.002 for diabetes
Biglycan-deficient (Bgn/) and wild-type (Bgn+/+) Ldlr/ mice were injected with vehicle (control) or STZ to cause diabetes (DM) and fed a 
0.12% cholesterol diet for 26 weeks. Weight gain is defined as weight at week 26  weight at day 0 (first day of diet, once hyperglycemia established) 
in grams. Insulin use is the number of mice per total enrolled mice per group that received insulin pellets; some mice may have received insulin more 
than once. Survival shows number of mice alive at week 26 per number of mice enrolled (%). Cholesterol and triglycerides were measured in 
nonfasting samples at week 26. Systolic blood pressure (sBP) was measured in individual mice in week 25 using a tail cuff apparatus. Renal and 
bioactive TGF- were measured in homogenized kidney samples from n = 4–6 per group. Data shown is mean ± SEM from N = 10–35 per group 
(number enrolled per group is shown in survival) unless otherwise specified.
aP < 0.05 for diabetes status within genotype.
bP < 0.05 for genotype within diabetes status.
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Fig. 1. TGF- and renal measures in biglycan deficiency. Biglycan wild-type (Bgn+/+; solid symbols) and  
biglycan-deficient (Bgn/; open symbols) Ldlr/ mice were injected with STZ to induce diabetes (DM; tri-
angles) or vehicle (ctrl; squares) and then fed a 0.12% cholesterol diet for 26 weeks. A, B: Blood glucose was 
measured weekly. Mean ± SEM is shown for N = 1035 per group. P < 0.001 for diabetic versus control groups. 
C, D: TGF- was measured at the indicated times. Mean ± SEM is shown for N = 8–34 per group. *P = 0.024 
for biglycan genotype effect in male nondiabetic mice and P < 0.001 for other pairwise comparisons. E, F: 
Mice were placed individually in metabolic cages every 4 weeks for the collection of 24 h urine samples for the 
determination of UAE/urinary creatinine excretion. Mean ± SEM is shown for N = 8–11 per group at each 
time point. *P < 0.001 for diabetic versus nondiabetic mice and for biglycan-deficient versus biglycan wild-type 
mice. G, H: Renal sections were stained with PAS and at least 20 glomeruli per mouse were scored using a 
semi-quantitative scale by two observers blinded to group. Mean ± SEM is shown for N = 7–16 per group. 
Panels A, C, E, and G, males; panels B, D, F, and H, females.
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(P < 0.05 for both males and females) and by biglycan defi-
ciency (P < 0.05 for both males and females) and there was 
a significant interaction between diabetes and biglycan 
genotype for males (P = 0.006; Table 1). Endogenously ac-
tive renal TGF- was significantly increased by biglycan de-
ficiency (P = 0.016) and diabetes (P < 0.001) for male mice 
(Table 1), but was not significantly different across groups 
for female mice (Table 1; near-significant P = 0.053 for 
diabetes).
Effect of biglycan deficiency on renal parameters
All groups had a progressive increase in urinary albumin 
excretion (UAE) over time, with much higher levels in dia-
betic mice (P < 0.001 vs. nondiabetics). UAE in biglycan-
deficient mice was significantly decreased compared with 
biglycan wild-type mice in both males and females, with 
UAE 30% lower than their biglycan wild-type counter-
parts over the time course (P < 0.001; Fig. 1E, F). Early DN 
is associated with renal hypertrophy and, in more advanced 
stages, renal atrophy is seen. Diabetes caused renal hyper-
trophy in both biglycan wild-type and biglycan-deficient 
mice (P  0.002 for both males and females); but in males, 
biglycan-deficient mice had significantly less renal hyper-
trophy than biglycan wild-type mice (P = 0.002; Table 1). In 
this murine model, we have previously demonstrated that 
diabetes causes increased mesangial matrix accumulation, 
as assessed by a semi-quantitative score (15). There was a 
tendency toward increased PAS score in diabetic compared 
with nondiabetic biglycan wild-type mice in both males 
and females, but this did not reach statistical significance. 
Biglycan deficiency may protect against mesangial matrix 
expansion, as biglycan-deficient diabetic mice did not dem-
onstrate increased PAS score compared with biglycan-
deficient nondiabetic mice in either gender; however, there 
were no statistically significant effects (Fig. 1G, H; supple-
mental Fig. S1). In male, but not female, mice, there was an 
increase in renal collagen staining in diabetic compared 
with nondiabetic mice (P = 0.04; supplemental Fig. S1), but 
there was no effect of biglycan deficiency. Furthermore, 
there was no difference in renal macrophage accumulation 
in either gender by biglycan genotype or diabetes status 
(not shown).
Biglycan deficiency does not affect renal apoB retention
Renal apoB accumulation was measured by Western blot 
and immunostaining. As expected (16), Western analysis 
demonstrated increased renal apoB content in diabetic 
mice compared with nondiabetic mice (P = 0.027), but there 
was no effect of biglycan deficiency (Fig. 2A, B). Immunos-
taining for apoB revealed a similar trend (supplemental 
Fig. S2A). Kidney sections were stained with oil red O, but 
there were no significant differences between groups (sup-
plemental Fig. S2B). Cholesterol content was also measured 
in renal tissue homogenates and did not differ between 
groups (supplemental Fig. S2C). Primary mesangial cells 
were isolated from nondiabetic biglycan-deficient or bigly-
can wild-type mice and LDL binding was measured. There 
was no significant difference in LDL binding to biglycan 
wild-type or biglycan-deficient cells (Fig. 2C). As all proteo-
glycans can bind apoB, the renal content of other proteo-
glycans was measured by immunoblot to see whether another 
proteoglycan was upregulated in biglycan-deficient mice. 
No substantial differences in the renal content of perlecan, 
Fig. 2. Renal lipid accumulation in biglycan deficiency. Biglycan 
wild-type (Bgn+/+; solid symbols) and biglycan-deficient (Bgn/; 
open symbols) Ldlr/ mice were injected with STZ to induce diabe-
tes (DM) or vehicle (C or ctrl) and then fed a 0.12% cholesterol diet 
for 26 weeks. A: Total renal protein was immunoblotted for apoB; 
actin is shown as the loading control. Shown are two mice per group 
representative of N = 6 per group. Molecular mass markers are 
shown to the left (in kDa). B: Blots were analyzed by densitometry. 
Mean ± SEM is shown. *P < 0.05 for diabetes effect within each gen-
otype. C: Isolated mesangial cells were incubated for 4 h with Alexa 
Fluor-labeled LDL and then washed; shown is Alexa Fluor intensity 
normalized to DAPI area. Mean ± SEM is shown for N = 5.
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decorin, versican, lumican, fibronectin, or fibromodulin 
were seen between biglycan-deficient or wild-type mice, or 
between control and diabetic mice (supplemental Fig. S3).
Effect of TGF- inhibition on metabolic parameters
As both systemic and renal TGF- were significantly in-
creased in biglycan-deficient mice, the experiments were 
repeated using administration of TGF--neutralizing anti-
body, 1D11, or irrelevant control antibody, 13C4. To mini-
mize animal use, only male diabetic mice were used. There 
was no significant effect of antibodies on susceptibility to 
STZ-induced diabetes. All mice gained weight through the 
study, but mice treated with 1D11 gained more weight than 
those treated with 13C4 (P = 0.02; Table 2). All mice in 
the study had elevated glucose levels throughout the study 
(Fig. 3A). There was no significant effect of genotype or 
either antibody on blood glucose levels. Mice received in-
sulin via subcutaneous pellets as needed; biglycan-deficient 
mice needed more insulin than biglycan wild-type mice 
(P = 0.002), but there was no effect of the 1D11 on insulin 
use (Table 2). No mice that received 1D11 in either geno-
type died of any cause during the study. However, 15% of 
biglycan-deficient and 18% of biglycan wild-type mice that 
received 13C4 died or were euthanized prior to the end of 
the study (Table 2, P = 0.011 for antibody effect). Choles-
terol increased over time in all groups (not shown), but did 
not significantly differ between groups (week 26 values 
shown in Table 2). After 26 weeks of diet, mice that re-
ceived 1D11 had approximately double the triglyceride lev-
els compared with those that received 13C4 (P = 0.019, 
Table 2) with no effect of genotype. There were no signifi-
cant differences in systolic blood pressure between any of 
the groups (Table 2).
Effectiveness of TGF- inhibition
Plasma TGF- was measured at least weekly and injec-
tions of 1D11 (and 13C4) were repeated when TGF- levels 
began to rise, which was every 8 weeks. As expected, use of 
the TGF--neutralizing antibody, 1D11, almost completely 
suppressed plasma TGF- levels (Fig. 3B, the curves for 
1D11-treated biglycan wild-type and biglycan-deficient mice 
overlap; P < 0.001 for 1D11 vs. 13C4 treatment within each 
genotype). In the 13C4-treated groups, there was an initial 
spike in TGF- levels immediately after STZ injections, 
then a gradual drop over the next 7 days. TGF- levels in 
13C4-treated biglycan wild-type mice remained at approxi-
mately 1,000–1,500 pg/ml for the duration of the study. 
However, in 13C4-treated biglycan-deficient mice, TGF- 
levels rose again after the first 5 weeks reaching levels of 
10,000–15,000 pg/ml after 10 weeks, and remained signifi-
cantly elevated over the rest of the study (P < 0.001 for 
13C4-treated biglycan wild-type vs. biglycan-deficient groups; 
Fig. 3B). The timing of the increase in TGF- levels in 
13C4-treated biglycan-deficient mice is similar to the onset 
of albuminuria (Fig. 3C). The 13C4-treated biglycan-
deficient mice had higher total and bioactive renal TGF- 
content than 13C4-treated biglycan wild-type mice (P < 0.05 
for each; Table 2); treatment with 1D11 lowered both total 
and bioactive renal TGF- compared with treatment with 
13C4 within each genotype (P  0.006 for each).
Effect of TGF- inhibition on renal parameters
There was a striking effect of 1D11 treatment to limit in-
creases in UAE in both genotypes (P < 0.001; Fig. 3C). UAE 
in 1D11-treated mice remained at levels similar to those seen 
in nondiabetic mice in our prior studies (compare Fig. 3C 
with Fig. 1E, F) (15, 16). Furthermore, mice that received 
1D11 had less renal hypertrophy compared with those that 
received 13C4 (P < 0.001; Table 2). However, there was no 
significant effect of 1D11 on PAS scores. Biglycan-deficient 
mice had slightly lower, but statistically significant, PAS 
scores than biglycan wild-type mice, but there was no sig-
nificant effect of 1D11 treatment (Fig. 3D; P = 0.038 for geno-
type; supplemental Fig. S4). There were no differences 
between groups in renal collagen content (supplemental 
Fig. S4) or renal macrophage accumulation (not shown).
TABLE 2. Effect of biglycan genotype and TGF- inhibition on metabolic parameters
Bgn+/+ 13C4 Bgn+/+ 1D11 Bgn/ 13C4 Bgn/ 1D11 P
Weight gain 5.6 ± 1.7 7.9 ± 1.3 4.4 ± 0.9 6.1 ± 0.8 0.02 for antibody effect
Insulin use (number treated/ 
total number)
7/17 (41%) 4/19 (21%) 12/27 (44%) 12/26 (46%) 0.002 for genotype
Survival, N (%) 14/17 (82.3%) 19/19 (100%) 23/27 (85.2%) 26/26 (100%) 0.011 for antibody effect
sBP (mm Hg) 123 ± 8 104 ± 9 115 ± 5 108 ± 6 NS
Cholesterol (mg/dl) 1,429 ± 108 1,461 ± 58 1,506 ± 67 1,383 ± 45 NS
Triglycerides (mg/dl) 263 ± 35 567 ± 130 284 ± 53 535 ± 82 0.019 for antibody effect
Total renal TGF- 374 ± 28 246 ± 11 589 ± 105 298 ± 32 0.03 for genotype and 0.002 for 
antibody effect
Bioactive renal TGF- 13 ± 1 5 ± 1a 19 ± 1b 5 ± 1a 0.011 for interaction
Renal weight/body weight (mg/g) 4.5 ± 0.2 3.5 ± 0.1 4.2 ± 0.1 3.6 ± 0.1 <0.001 for antibody
Biglycan-deficient (Bgn/) and wild-type (Bgn+/+) Ldlr/ mice were injected with STZ to cause diabetes and concurrently injected with TGF--
neutralizing antibody, 1D11, or irrelevant control antibody, 13C4, at 2 mg/kg ip on the first day of STZ injections. Mice were fed a 0.12% cholesterol 
diet for 26 weeks. Weight gain is defined as weight at week 26  weight at day 0 (first day of diet, once hyperglycemia established) in grams (this P 
value was derived from the time/antibody interaction term in a linear mixed model for weight). Insulin use is the number of mice per total enrolled 
mice per group that received insulin pellets; some mice may have received insulin more than once. Survival shows number of mice alive at week 26 
per number of mice enrolled (%). Cholesterol and triglycerides were measured in nonfasting samples at week 26. Systolic blood pressure (sBP) was 
measured in individual mice in week 25 using a tail cuff apparatus. Renal and bioactive TGF- were measured in homogenized kidney samples from 
n = 4–6 per group. Data shown is mean ± SEM from N = 17–27 per group (number enrolled per group is shown in survival) unless otherwise specified.
aP < 0.05 for diabetes status within genotype.
bP < 0.05 for genotype within diabetes status.
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Effect of TGF- inhibition on renal apoB accumulation
Treatment with 1D11 significantly decreased renal apoB 
content determined by Western blot within both genotypes 
(Fig. 4A, B; P = 0.002). Immunostaining for apoB revealed 
a similar pattern (supplemental Fig. S5A). Kidney sections 
were stained with oil red O, but there were no significant 
differences between groups (supplemental Fig. S5B). Cho-
lesterol content was also measured in renal tissue homog-
enates and did not differ between groups (supplemental 
Fig. S5C). Primary mesangial cells were isolated from non-
diabetic biglycan wild-type or biglycan-deficient cells; cells 
were treated ex vivo with TGF- or vehicle and with 13C4 
or 1D11, then LDL binding was measured. In the absence 
of TGF- stimulation, there were significant main effects 
for antibody (P = 0.029) and biglycan genotype (P = 0.013) 
on LDL binding; in the presence of TGF- stimulation, 
there was less LDL binding in 1D11-treated compared with 
13C4-treated cells (P < 0.0001; Fig. 4C). As expected, no 
biglycan was detectable in cells isolated from biglycan-defi-
cient mice. Biglycan content was increased by TGF- stimu-
lation, which was inhibited by the presence of 1D11 in cells 
isolated from biglycan wild-type mice (Fig. 4D).
Fig. 3. Effect of TGF- inhibition. Biglycan wild-type (Bgn+/+; solid symbols) and biglycan-deficient (Bgn/; open symbols) male Ldlr/ 
mice were injected with STZ and concurrently injected with TGF--neutralizing antibody, 1D11 (triangles), or irrelevant control antibody, 
13C4 (squares), at 2 mg/kg ip. One week later, all mice were placed on a 0.12% cholesterol diet. A: Blood glucose was measured at the indi-
cated times (mean ± SEM is shown for N = 13–26 per group). There were no significant differences between groups. B: Total TGF- was 
measured at least weekly. The 1D11 or 13C4 were reinjected every 8 weeks as indicated by arrows. Data shown is mean ± SEM for N = 17–27 
per group; not every mouse was bled at each time point so the number of mice at each time point varies from 2 to 27 per group. P < 0.001 
for 13C4-treated biglycan wild-type versus 13C4-treated biglycan-deficient mice; P < 0.001 for 1D11 versus 13C4 treatment within each geno-
type. The curves for 1D11-treated mice overlap. C: Mice were placed individually in metabolic cages every 4 weeks for the collection of 24 h 
urine samples for the determination of UAE/urinary creatinine excretion. Mean ± SEM is shown for N = 6–10 per group at each time point. 
*P < 0.001 for effect of antibody. D: Renal sections were stained with PAS and scored using a semi-quantitative scale by two observers blinded
to group with scores averaged. Data shown is the mean ± SEM for N = 7–10 per group. Groups without a common letter are significantly
different.
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DISCUSSION
In summary, biglycan deficiency led to a modest decrease 
in UAE, but there was no significant effect on renal apoB 
accumulation. There was a striking elevation in TGF- in 
biglycan-deficient mice. Although we did not find any com-
pensatory increase in other proteoglycans in biglycan-
deficient mice, the lack of biglycan did not significantly 
affect renal apoB accumulation implying that other proteo-
glycans (or, indeed, other mechanisms) contribute to renal 
Fig. 4. Renal lipid accumulation. Biglycan wild-type (Bgn+/+) and biglycan-deficient (Bgn/) male Ldlr/ mice were injected with STZ 
and concurrently injected with TGF--neutralizing antibody, 1D11 (solid bars), or irrelevant control antibody, 13C4 (open bars), at 2 mg/kg ip. 
One week later, all mice were placed on a 0.12% cholesterol diet. A: Total renal protein was immunoblotted for apoB; actin is shown as the 
loading control. Shown are two mice per group representative of N = 6 per group. Molecular mass markers are shown to the left (in kDa). 
B: Blots were analyzed by densitometry. Mean ± SEM is shown. *P = 0.002 for antibody effect. C: Mesangial cells isolated from biglycan-defi-
cient or biglycan wild-type mice were treated with TGF- (2 ng/ml) or vehicle and with 1D11 or 13C4 (10 g/ml) for 24 h and then washed 
and incubated for 4 h with Alexa Fluor-labeled LDL; shown is Alexa Fluor intensity normalized to DAPI area. Mean ± SEM is shown for N = 5. 
*P  0.05 or **P < 0.0001 for antibody effect; aP < 0.05 for genotype effect. D: Cell protein from parallel wells was immunoblotted for bigly-
can; actin is shown as the loading control. The blot shown is representative of three separate experiments.
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apoB retention. TGF- leads to the elongation of GAG chains 
in many proteoglycans (4, 26–28). Proteoglycan-lipoprotein 
interactions are ionic in nature, with binding occurring be-
tween negatively charged GAG chains and positive residues 
on apoB or apoE. Thus, the elevated TGF- in biglycan-
deficient mice may have led to elongated GAG chains on 
other proteoglycan species, which could then bind LDL, 
even in the absence of biglycan. This is supported by the 
finding that TGF- inhibition prevented renal apoB accumu-
lation and decreased LDL binding to primary mesangial cells 
ex vivo. When biglycan-deficient mice were treated with the 
TGF--neutralizing antibody, 1D11, there was a suppression 
of UAE to levels seen in nondiabetic mice (compare Fig. 3C 
with Fig. 1E, F), and prevention of renal hypertrophy. Fur-
thermore, 1D11-treated mice had improved survival and in-
creased weight gain. While these data do not definitively 
prove cause and effect, it is striking that neutralization of 
TGF- led to decreased renal apoB accumulation, decreased 
albuminuria, and improved mortality, suggesting that renal 
apoB accumulation contributes to renal disease development.
TGF- and renal diseases
Extensive work has demonstrated a key role for TGF- in 
the pathogenesis of renal diseases, including DN. The TGF- 
superfamily has three isoforms, named TGF-1, -2, and -3. 
All three isoforms are expressed in the kidney, as are all three 
TGF- receptor isoforms. TGF- signaling within the kidney 
induces both pro-fibrotic Smads (Smad2 and Smad3), as well 
as the anti-inflammatory and anti-fibrotic inhibitory Smad7. 
Diabetes increases renal TGF- as well as systemic TGF- 
levels. The elevations in TGF- are due to hyperglycemia 
directly, as well as through increased protein traffic in the 
glomerulus and increased angiotensin II [for review see 
(29)]. The timing of the second elevation of TGF- seen in 
13C4-treated biglycan-deficient mice coincides with the onset 
of albuminuria, implying that the onset of renal injury led to 
this increase in TGF-. Inhibition of TGF- has been shown 
to limit development of DN and other renal diseases (30–33); 
however, studies have not consistently shown effects of 
TGF- antagonism on proteinuria. Addition of agents an-
tagonizing the renin angiotensin pathway provide further 
benefits in DN, including reduction in proteinuria. Decorin 
and biglycan are closely related proteoglycans that are thought 
to be natural inhibitors of TGF-. Indeed, prior studies 
have used decorin as a TGF--neutralizing agent and found 
renal protection (34, 35). We and others have previously 
demonstrated increases in both systemic and tissue TGF- in 
biglycan-deficient mice (18, 23, 36). We have now demon-
strated that suppression of this elevation in TGF- pro-
vides further reduction in DN in this murine model of 
biglycan deficiency. Thus, this data provides further evidence 
in support of biglycan playing a major role in the regulation 
of TGF- activity, and adds to the literature demonstrating 
renal protective effects of TGF- inhibition.
Decreased renal apoB accumulation
In previous studies using cultured cells, we and others 
have demonstrated that TGF- leads to upregulation of bi-
glycan core protein and elongation of the GAG chains on 
many proteoglycans (28, 37–39). We have further shown 
that proteoglycans from TGF--treated cells have increased 
lipoprotein binding (4, 10, 37). Proteoglycans bind lipo-
proteins via ionic interactions between negatively charged 
sulfate and carboxylic acid groups on GAG chains and posi-
tively charged residues on lipoproteins. Elongation of GAG 
chains is accompanied by increased sulfation, which ac-
counts for the increased lipoprotein binding affinity of 
proteoglycans synthesized by cells stimulated with TGF- 
(37). In previous studies, we demonstrated that suppres-
sion of TGF- using 1D11 decreased lipoprotein binding to 
primary vascular smooth muscle cells (25); we now show a 
similar decrease in lipoprotein binding in primary mesan-
gial cells. We propose that the decrease in renal apoB con-
tent observed in 1D11-treated mice is due to prevention of 
GAG chain elongation and, thus, decreased lipoprotein 
binding affinity. We did not find any compensatory increase 
in other renal proteoglycans in biglycan-deficient compared 
with biglycan wild-type mice in the present study; thus, it 
remains unclear which proteoglycans contribute to renal 
apoB accumulation. However, the lack of decreased renal 
apoB retention or LDL binding in biglycan deficiency im-
plies redundancy of proteoglycans. Indeed all proteogly-
cans are capable of binding to lipoproteins, and binding is 
driven mainly by elongated GAG chains [for review see 
(5)]. However, given that inhibition of TGF- alone does not 
consistently reduce proteinuria (40–42), we speculate that 
the decreased renal apoB accumulation observed in this 
study contributed to the decreased proteinuria observed.
Elevated triglycerides
Somewhat surprisingly, we found elevated triglycerides 
in mice that received 1D11. High triglycerides have been 
found to be a risk factor for the development of chronic 
kidney disease (43, 44) and one study found that high tri-
glycerides were associated with altered levels of urea nitro-
gen, glomerular filtration rate, and creatinine, as well as an 
increased risk of chronic kidney diseases (45). Thus, per-
haps the benefit of TGF- neutralization is negated, at least 
in part, by the effect of elevated triglycerides in 1D11-
treated mice. The cause of elevated triglycerides in 1D11-
treated mice is unclear and this finding is inconsistent with 
the literature. In a previous study using 1D11 in nondiabetic 
LDLR/ mice, we did not find effects of 1D11 on triglycer-
ides (45). Furthermore, another study reported a decrease 
in triglycerides (along with decreased adiposity and insulin 
resistance) using 1D11 (46). Further work is necessary to 
determine whether inhibition of TGF- has negative im-
pacts on triglyceride metabolism.
1D11 doses
The 1D11 is a pan-TGF--neutralizing antibody that has 
been extensively studied in a number of animal models 
and a closely related molecule, fresolimumab, has been ex-
amined in clinical studies. Inhibition of TGF- has potential 
therapeutic impact in a number of pathologies, including 
renal diseases and several forms of cancer, systemic sclero-
sis, myelofibrosis, and others. In most of the animal studies, 
the antibody is injected multiple times per week (47–49) 
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and 1D11 is suggested to have a half-life of approximately 
34 h (47). However, in our study, we measured TGF- lev-
els weekly after injections of 1D11 or 13C4 and only re-
administered antibodies when TGF- levels began to rise, 
which was every 8 weeks. For most of the 8 weeks after each 
injection, TGF- was undetectable in 1D11-treated mice, 
and once it was detectable, mice were reinjected. In a prior 
study investigating the role of TGF- induction in angio-
tensin-induced atherosclerosis, we injected 1D11 only once 
(at the time of placement of angiotensin II delivery pumps) 
and found that this prevented elevation in TGF- for at 
least 28 days. To our knowledge, we are the first to demon-
strate prolonged effects of this antibody in suppressing 
TGF-. Further study will be necessary to determine the 
mechanism of this prolonged suppression, but this obser-
vation has important clinical and economic impacts.
TGF- and mortality
TGF- neutralization with 1D11 significantly increased 
survival in both genotypes, suggesting that elevated TGF- 
may contribute to mortality in this model of DN. In fact, no 
animal that received 1D11 died from any cause during the 
study; however, 15–18% of mice that received 13C4 died or 
were euthanized according to study protocol, consistent 
with our prior work [Table 2 and (16)]. Therefore, the de-
creased survival seen in 13C4- versus 1D11-injected mice is 
not likely due to a toxic effect of 13C4. Instead the 13C4 
antibody may simply confer no protection against diabetes 
complications, while inhibition of TGF- may be therapeu-
tic in diabetes by prolonging survival. Treatment with 1D11 
led to increased weight gain compared with treatment with 
13C4, and the 1D11-treated mice had decreased renal 
apoB accumulation and renal injury. These are possible 
mechanisms that may account for the improved survival. As 
renal diseases are associated with increased mortality, the 
finding of improved survival is of great importance, and 
ongoing clinical studies are of interest to see whether simi-
lar findings are found in humans.
In summary, this study provides further evidence that 
renal apoB accumulation contributes to DN. Prevention 
of renal apoB accumulation by TGF- inhibition led to im-
proved survival and renal outcomes. However, lipid-lower-
ing therapy has not been shown to reduce the progression 
of DN in human studies (50). We acknowledge that the 
role of renal apoB accumulation may differ between mu-
rine and human DN, and we recognize that our study did 
not include an exhaustive evaluation of mechanisms in-
volved in lipid uptake in the kidney. Nevertheless, prevention 
of renal apoB accumulation may be yet another mecha-
nism by which TGF- inhibition is renally protective. 
Furthermore, this study provides further evidence that bi-
glycan has a major role in the regulation of TGF- activity. 
A limitation of our study was that we did not study the ef-
fects of TGF- or its inhibition on protein dynamics of 
ECM proteins or proteoglycans. Further work investigat-
ing the impact of TGF- inhibition on renal structure and 
function are needed, and ongoing clinical trials investigat-
ing TGF- inhibition in clinical diseases will be of great 
interest.
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